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Abstract
Background: In spite of advances in psychotherapy and pharmacotherapy, there are still a significant number of
patients with depression and obsessive-compulsive disorder that are not aided by either intervention. Although still
in the experimental stage, deep brain stimulation (DBS) offers many advantages over other physically-invasive
procedures as a treatment for these psychiatric disorders. The purpose of this study is to systematically review
reports on clinical trials of DBS for obsessive-compulsive disorder (OCD) and treatment-resistant depression (TRD).
Locations for stimulation, success rates and effects of the stimulation on brain metabolism are noted when
available. The first observation of the effects of DBS on OCD and TRD came in the course of using DBS to treat
movement disorders. Reports of changes in OCD and depression during such studies are reviewed with particular
attention to electrode locations and associated adverse events; although these reports were adventitious
observations rather than planned. Subsequent studies have been guided by more precise theories of structures
involved in DBS and OICD. This study suggests stimulation sites and prognostic indicators for DBS. We also briefly
review tractography, a relatively new procedure that holds great promise for the further development of DBS.
Methods: Articles were retrieved from MEDLINE via PubMed. Relevant references in retrieved articles were
followed up. We included all articles reporting on studies of patients selected for having OCD or TRD. Adequacy of
the selected studies was evaluated by the Jadad scale. Evaluation criteria included: number of patients, use of
recognized psychiatric rating scales, and use of brain blood flow measurements. Success rates classified as
“improved” or “recovered” were recorded. Studies of DBS for movement disorders were included if they reported
coincidental relief of depression or reduction in OCD. Most of the studies involved small numbers of subjects so
individual studies were reviewed.
Results: While the number of cases was small, these were extremely treatment-resistant patients. While not
everyone responded, about half the patients did show dramatic improvement. Associated adverse events were
generally trivial in younger psychiatric patients but often severe in older movement disorder patients. The
procedures differed from study to study, and the numbers of patients was usually too small to do meaningful
statistics or make valid inferences as to who will respond to treatment.
Conclusions: DBS is considered a promising technique for OCD and TRD. Outstanding questions about patient
selection and electrode placement can probably be resolved by (a) larger studies, (b) genetic studies and (c)
imaging studies (MRI, fMRI, PET, and tractography).
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In the middle of the twentieth century, the lesioning of
areas of the brain was discovered to be an effective treat-
ment for certain movement disorders. Unfortunately,
there were damaging side effects as a result of these
lesions. In the 1980s, it was determined that the same
effects could be accomplished by stimulating the tissue
with electricity. DBS was approved by the FDA as a treat-
ment for movement disorders in 2002. Although still in
the research stage, DBS appears to also be a major
advance in the treatment of obsessive compulsive disor-
der (OCD) and treatment resistant depression (TRD).
Electrophysiology and modern imaging allow the very
precise placement of electrodes. Response can be opti-
mized by changing location and adjusting stimulus site
parameters. Since the patient cannot detect the simula-
tion, periods of active stimulation and sham (zero vol-
tage) can be alternated to provide single or double-blind
controls.
Stimulation usually has a pulse width around 60
microseconds delivered at 130 Hz, although there are
variations on these parameters depending on the target.
Bipolar and monopolar electrodes have been used;
monopolar electrodes were contact cathode and case
anode. After the sites and parameters for DBS are
selected, the stimulator is placed under the skin, usually
below the clavicle, and connecting wires are run under
the skin to the stimulating electrodes in the brain.
Although the sites for stimulation vary, they basically
fall into two groups: a basal ganglia group and a cingu-
late gyrus group.
The primary purpose of this article is to summarize all
clinical trials of DBS in OCD and TRD, with particular
attention to outcomes and electrode locations.
Methods
Searching
We conducted a comprehensive search using MED-
LINE/PubMed in May 2009, using different combina-
tions of the following MeSH and free text terms: deep
brain stimulation, DBS, obsessive-compulsive disorder,
OCD, depression. Searches were restricted to human
studies, clinical trials, and reviews. Reference lists from
retrieved reports were reviewed for additional relevant
studies. Unpublished data were not sought and there
were no language restrictions. [See Additional file 1 for
a Quality of Reporting of Meta-analyses (QUOROM)
statement checklist.]
Selection
We included human studies that assessed the efficacy of
DBS on psychiatric symptoms for OCD, TRD, or both.
We accepted papers with only one case if they included
some estimate of efficacy. In general, discussions of ethi-
cal issues were not reviewed. Articles discussing only
physical measurements (e.g., cerebral blood flow) or
transient effects (e.g., smiling) were rejected from the
main analysis but some were referenced in the
discussion.
Validity assessment
Each of the primary studies were rated using the Jadad
scale [1], but see Berger 2006 for critical commentary
[2]. This scale gives one point for each of the following,
(a) randomization, (b) randomization appropriate and
well-described, (c) double-blind, (d) double-blind appro-
priate and well-described, and (e) withdrawals and drop-
outs described. No studies were excluded for poor
scores. Psychiatric rating scales and cerebral blood flow
studies were noted when used. Improvement of these
severely ill patients by chance has a very low probability
and that the nature of DBS lends itself to using the
patient as its own control, by simply turning off the sti-
mulator, as there is usually no sensation from DBS. This
is almost universally taken advantage of in past studies.
On the negative side, many studies were small, and
actual techniques so complex that between-study com-
parison was ineffective.
Data abstraction
Data were extracted independently by the authors and
any disagreements were resolved by consensus.
Analysis
Due to the differences in outcome measures used in the
trials, a quantitative analysis of the data was deemed
inappropriate. A qualitative summary of the data was
consequently completed.
Results
Flow of included studies
Electronic searches found 49 studies that were poten-
tially relevant to the present systematic review. Of these,
16 met the inclusion/exclusion criteria (see Figure 1 for
a flow diagram). Of the 33 that did not meet the criteria,
12 were excluded from the main review because they
investigated DBS primarily for movement disorders with
only incidental observation of psychological side effects
on depressive or OCD symptoms. Papers that did not
explicitly deal with the psychiatric symptoms of patients
were excluded. However, 21 of the excluded papers are
listed as reviews and some are also cited in the discus-
sion. Papers that were mainly discussions of philosophi-
cal and ethical issues were not reviewed at all.
We found reference to a relatively new procedure
called tractography [3]. Tractography is a magnetic
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ships in the human brain between a “seed” location and
those structures to which the seed has functional con-
nections. This is highly relevant for future selection of
DBS targets and is briefly described in the discussion
section.
Study characteristics
Sixteen studies published between 1999 and 2009 were
selected for review: nine for OCD [4-12], seven for TRD
[10,13-18], and one for both disorders [19] (in Jimenez
et al., 2007 [10], one patient with OCD and another
with TRD underwent DBS). These studies included a
total of 42 patients with OCD who were treated with
DBS, 67 patients with TRD, and one with both OCD
and TRD. Length of study ranged from 3 to 39 months.
All availed themselves of the use of patients as their
own controls by turning stimulation on and off (single-
blind), but Table 1 indicates those that had the clinical
observations made blind (double-blind). Randomization
of patient selection was never used although random
selection of active/sham sessions was.
There are a number of generally accepted measures
of well-being, depression, and OCD, and we have indi-
cated the ones used in the major studies. For general
well-being there are the Global Assessment Scale
(GAS), Clinical Global Impressions (CGI) scale, Global
Assessment of Function (GAF), and Positive and Nega-
tive Affects Scales (PANAS). For OCD, the standard is
the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
For TRD, the standard assessments include the Hamil-
ton Depression Rating Scale (HDRS), the Montgom-
ery-Asberg Depression Rating Scale (MADRAS), Beck
Depression Inventory (BDI), and Beck Anxiety Inven-
tory (BAI). There is also the Brief Psychiatric Rating
Scale (BPRS), Profile of Mood States (PMOS), and
Self-Rating Depression Scale (SDS) used in some
studies.
See Table 1 for specific characteristics of each
reviewed study. The table shows primary psychiatric
diagnoses, Jadad scores, numbers of subjects starting
and numbers completing, durations of studies, methods
of cerebral blood flow measurement (if assessed), clinical
r a t i n g ss c a l e su s e d ,l o c a t i o n so fD B S ,a d v e r s ee v e n t s
reported (if more than minor surgical squeals), numbers
and percent improved, numbers and percent recovered,
and whether ratings were done double-blind.
Reports on patients with OCD
Nuttin et al.,1999 [4] (POMS). There were six patients
with severe OCD. Quadripolar electrodes were
implanted into the anterior limb of the internal capsule
(AL/IC). Four patients continued for 21 months. One
patient was unchanged and three were much improved
Figure 1 Flow diagram of included studies.
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Study Jadad
score
Double
blind
No. of
patients
(started/
finished)
Final
observation
period
(months)
Cerebral
blood
flow
Clinical
scales
DBS
location
Adverse effects* Patients
improved
Patients
recovered
OCD Nuttin
1999 [4]
3 Yes 6/4 21 fMRI, PET POMS AL/IC 3 (75%)
Gabriels
2003 [5]
0 No 3/3 33-39 BPRS, POMS,
Y-BOCS
AL/IC 2 (66%)
Nuttin
2003 [6]
4 Yes 6/4 21 fMRI, PET CGI, Y-BOCS AL/IC,
DMNT
3 (50%)
Sturm
2003 [7]
0 No 4/4 30-34 fMRI, PET Right
NA
4 (100%)
Abelson
2005 [8]
3 No 4/4 10 PET GAF, HDRS AL/IC Mild dizziness 3 (75%) 1 (25%)
Greenberg
2006 [9]
4 Yes 10/8 36 HDRS, Y-
BOCS
AL/IC,
VC/C
Seizure, hypomania,
relapse with battery
failure
2 (25%) 4 (50%)
Jimenez
2007** [10]
0 Yes 1/1 GAF ITP 1 (100%) 1 (100%)
Mallet
2008 [11]
4 Yes 18/168 3 GAF, CGI
MADRAS,
MDRS, MINI,
Y-BOCS
STN 15 major including
a brain hemorrhage,
22 minor adverse
events
10 (62%) 4 (25%)
Nuttin
2008 [12]
4 Yes 6/6 21 PET CGI, Y-BOCS AL/IC 3 (75%)
TRD Jimenez
2005 [13]
0 No 1/1 24 HDRS ITP 1 (100%)
Mayberg
2005 [14]
3 Yes 6/6 6 PET CGI, HDRS,
MADRS,
PANAS
CG 4 (66%)
Schlapfer
2005 [15]
4 Yes 3/3 PET 3 (100%)
Jimenez
2007** [10]
0 No 1/1 HDRS, GAS ITP 1 (100%)
Lozano
2008 [16]
4 Yes 20/20 12 PET BAI, BDI,
CGI, HDRS
CG 12 (60%) 7 (35%)
Malone
2009 [17]
4 No 15/15 15 CGI, GAF,
HDRS,
MADRS
VC/CS 6 (40%)
Wang 2009
[18]
0 Yes 21/21*** HDRS STN
OCD
and
TRD
Aouizerate
2009 [19]
0 1/1 15 HDRS, Y-
BOCS
LCa, NA 1 (100%)
AL/IC, anterior limbs of internal capsule; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BPRS, Brief Psychiatric Rating Scale; CG, cingulate gyrus; CGI,
Clinical Global Impressions; DMNT, dorsa-medial nucleus of the thalamus; GAF, Global Assessment of Function; GAS, Global Assessment Scale; ITP, inferior
thalamic peduncle; LCa, limbic caudate; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; MDRS, Mattis Dementia
Rating Scale; MINI, Mini International Neuropsychiatric Interview; NA, nucleus accumbens; PANAS, Positive and Negative Affects Scales; PET, positron emission
tomography; PMOS, Profile of Mood States; STN, subthalamic nucleus; VC/CS, ventral capsule/ventral striatum; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
Blank cells indicate that there were no data on that subject in the paper.
*Other than minor surgical effects.
**In this study, one patient with OCD and another with TRD underwent DBS.
***Patients on anti-Parkinson drugs were controls.
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regional activity as measured by functional MRI (fMRI)
and positron emission tomography (PET) scan.
Gabriels et al., 2003 [5] (BPRS, POMS, Y-BOCS).
Three severe OCD patients were treated with DBS to
the anterior limbs of the internal capsules. One patient
with somatoform symptoms showed no improvement.
The two others essentially recovered. Their gains
endured with minimal adverse events.
Nuttin et al., 2003 [6] (CGI, Y-BOCS). Six patients
were implanted with quadripolar electrodes in AL/IC.
Four were evaluated double-blind. One was unchanged
and three greatly improved after 21 months. The non-
responder was preoccupied with body hair but failed to
fulfill the criteria for body dimorphic disorder.
Strum et al., 2003 [7]. Four treatment-resistant OCD
patients with co-morbid severe anxiety disorder received
DBS to the right nucleus accumbens. Bilateral stimuli
did not improve results. Three of the four had total
remissions over 24 to 30 months.
Abelson et al., 2005 [8] (GAF, HDRS). Using hard-
ware developed for the treatment of movement disor-
der, four patients with chronic intractable OCD were
treated with leads placed bilaterally in the anterior
limbs of their anterior capsules. They received random
four-week blocks of stimulus on and off. Dramatic
improvement was seen in one patient and a second
showed moderate improvement. The unimproved
patient failed to show the regional cerebral blood flow
(rCBF) changes seen in patients who responded to
treatment, referred to in this discussion as responders.
Residual depression left one OCD responder unable to
function normally.
Greenberg et al., 2006 [9] (HDRS, Y-BOCS). Ten OCD
patients with severe treatment-resistant OCD had quadra-
polar leads implanted rostral to the anterior commisure
extending into the ventral capsule and ventral commisure.
Patients were followed for 36 months. Four patients had
improvement greater than 34% based on the Yale-Brown
Obsessive Compulsive Scale. Two patients had declines
between 25 and 35%. Incidental mention is made of
improvement of depression. Side effects included an
asymptomatic hemorrhage, seizure, superficial infection,
worsening of symptoms when DBS stopped due to battery
failure, and transient hypomanic symptoms.
Jimenez et al., 2007 [10] (GAF). See also under TRD.
A female with depression for 23 years and a male with
obsessive-compulsive disorder for nine years had stereo-
tactic implantation of electrodes in the inferior thalamic
peduncle. Using the GAF scale, both cases showed
improvement.
M a l l e te ta l . ,2 0 0 8[ 1 1 ]( G A F ,G A I ,M A D R A S ,Y -
BOCS, CGI, MDRS, Mattis Dementia Rating Scale, Mini
International Neuropsychiatric Interview). There were
16 patients in a multi-center study of severe OCD. They
used randomized crossover design with 10 months sub-
thalamic or sham stimulation. There were significant
improvements in OCD with active stimulation, but
there were 15 major (including a brain hemorrhage) and
23 minor adverse events. Four of the patients recovered,
using a Y-BOCS of 6 or less as an indicator of recovery.
It was noted that there was no improvement in depres-
sion although hypomania was one of the adverse events.
Nuttin et al., 2008 [12] (CGI, Y-BOCS). DBS electro-
des were inserted into the anterior limbs of the internal
capsule of six severe OCD patients. Stimuli caused an
increase in fMRI signal, particularly in the pons. PET
scans at three months showed lower frontal metabolism.
Symptoms were much improved in three patients and
unchanged in one by 21 months.
Reports of patients with TRD
Jimenez et al., 2005 [13] (HDRS). The patient was a 48-
year-old woman with TRD. Tetrapolar-stimulating elec-
trodes were implanted bilaterally in the inferior thalamic
peduncles. Stimulation was 130 Hz, .45 ms pulse width
and 2.5 volts. At 24 months, the woman had a sustained
recovery with minimal adverse events.
Mayberg et al., 2005 [14] (CGI, HDRS, MADRAS,
PANAS). Six patients with severe chronic TRD were trea-
ted. On stimulation of white matter adjacent to the sub-
genual cingulate gyrus, all subjects reported acute effects
that included calmness, heightened awareness, and
increased visual acuity. Chronic treatment resulted in
sustained remissions in four of the six patients at the six-
month evaluation mark with associated improvements in
performance and sleep. Antidepressant effects were asso-
ciated with a reduction in rCBF in local and down-stream
limbic and cortical sites. Adverse events were minor and
included skin infections in two patients and erosion over
the hardware. There was a suggestion that non-respon-
ders were atypical depressives with late onsets.
Schlaepfer et al., 2005 [15]. Three patients with TRD
were implanted with bilateral DBS electrodes in the
nucleus accumbens. Stimulation parameters were modi-
fied in a double-blind manner, and clinical ratings
assessed at each modification. Brain metabolism was
assessed one week before and one week after stimula-
tion. Clinical ratings improved in all three patients when
the stimulator was on, and worsened in all three
patients when the stimulator was off. Effects were
observed immediately, and no side effects occurred in
any of the patients. Using PET, significant changes in
brain metabolism as a function of the stimulation in
frontostriatal networks were observed.
Jimenez et al., 2007 [10] (GAS, HDRS). See also under
OCD. One patient with inferior thalamic peduncle DBS
recovered.
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Page 5 of 9Lozano et al., 2008 [16] (BDI, BAI, BDI, CGI, HDRS).
Twenty patients with TRD underwent serial assessments
before and after DBS of the subcallosal cingulate gyrus.
One month after surgery, 35% of patients were respon-
ders and 10% were in remission. Six months after sur-
gery, 60% were responders and 35% were in remission.
Benefits were maintained at 12 months. DBS was asso-
ciated with changes in the metabolic activity of cortical
and limbic circuits implicated in the pathogenesis of
depression. Adverse effects were trivial and transient.
Malone et al., 2009 [17] (CGI, GAF, HDRS,
MADRAS). Fifteen TRD patients were given ventral
caudate-ventral striatum DBS. At six months, nearly
50% of patients responded and 20% achieved remission.
At the last examination (six months to four years), there
were about the same number of responders and 40% of
patients were in remission.
Wang et al., 2009 [18] (HDRS, SDS). Using a subthala-
mic nucleus (STN)-DBS group (n = 27) and an anti-Par-
kinson’s medication control group, evaluation of
depression and motor function was performed six times
using SDS and HDRS. Depression decreased notably
within six months postoperatively. The mean value of
the bilateral voltages was correlated with SDS and
HDRS scores (P < 0.05). The improvement in motor
symptoms resulting from STN-DBS can improve depres-
sion in Parkinson’s disease (PD) patients, but its long-
term effects were unremarkable. Within the treatment
range, the mean value of bilateral voltages correlated
with severity of depression in PD patients.
Reports of patients with both OCD and TRD
Aouizerate et al., 2009 [19] (HDRS, Y-BOCS). The first case
was also reported in 2004 [20]. Two patients with intract-
able depression and OCD were treated with DBS. Caudate
stimulation relieved the OCD symptoms while nucleus
accumbens-stimulation improved depressive symptoms.
Discussion
For as long as the brain has been seen as the site of mental
activity, it has followed that altering brain function should
be implemented to treat mental illness. Second generation
antidepressants and psychotherapy are currently the least
invasive ways of affecting brain function [21,22] but they
leave too many patients only partially improved, and have
proved completely ineffective for some. Estimates of treat-
ment unresponsiveness are unreliable, but 30% to 40%
patients with depression and OCD probably become treat-
ment failures. For these patients, techniques like DBS pro-
vide a promising treatment alternative.
Limitations of this study
Currently, the chief problem is that current studies are
too small to support valid inferences about patient
selection and choice of stimulation locations. In the pre-
ceding sections, relevant studies have been summarized
since the sparse data precludes combining them for
meta-analysis.
There is a wealth of data in pain and movement disor-
der literature which has not been analyzed in detail.
However, the survey given above suggests that DBS is
not entirely benign; the reports of suicides and psy-
choses are disturbing. Nevertheless, it is difficult to draw
general conclusions only from studies which gave inci-
dental attention to OCD and TRD in DBS for move-
ment disorder reports.
The basal ganglia are complex, with some subdivisions
small and tightly packed together. In spite of the sophis-
ticated imaging and electrophysiology techniques, locali-
zations often remain less than exact.
Last year, Elsevier launched a new journal titled “Brain
Stimulation.” Among publications in other journals, the
following references were selected as being of potential
interest to the reader: [23-40]. Some of these have also
been referred to in the discussion.
Anatomy of DBS sites
The thalamic/capsular area is favored for treatment of
OCD. A useful review of the basal ganglia areas is to be
found in the paper by Kopell [41]. The various locations
for DBS in TRD include orbito-frontal cortex, anterior
cingulate gyrus, corpus striatum, globus pallidus, sub-
genual cingulate, ventral capsule/ventral striatum, ven-
tral capsule/ventral commisure, nucleus accumbens, and
inferior thalamic peduncle. Based on current technology
and understanding of psychiatric circuitry, there seems
to be two main areas where DBS can affect TRD: the
cingulate white matter and the AL/IC. Nuttin [6]
reported on one patient who had stimulation delivered
both to the AL/IC and to the dorsa-medial nucleus of
the thalamus (DMNT). Symptoms, word fluency and
memory improved with AL/IC stimulation and wor-
sened with DMNT. Stimulating the internal capsule,
Okun [42] found non-mood-related responses, such as
taste and smell, significantly associated with the ventral
lead. Mayberg [14] found hyperactivity in the subgenual
cingulate (BA25) along with hypoactivity in prefrontal
(BA9/46), premotor (BA6), dorsal anterior cingulate
(BA24) and anterior insula in all treatment-resistant
patients. Responders had greater prefrontal hypoactivity
and an area of hyperactivity in the medial frontal cortex
(BA10).
New insights into functional brain anatomy
Measurement of rCBF can be used to trace interrelation-
ships between areas of the brain and to see if DBS has had
an effect and it may also have prognostic value. Many of
the areas that are supposedly affected by DBS are
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metabolism may characterize some non-responders.
rCBF has traditionally been measured using PET.
Radionuclides used in PET are typically isotopes with
short half-lives such as carbon-11 (~20 min.), nitrogen-
13 (~10 min.), oxygen-15 (~2 min.), and fluorine-18
(~110 min.). They must be delivered from a cyclotron
and synthesized into organic compounds within min-
utes, so the procedure is limited to special facilities.
Using PET, Seminowicz et al. [36] reported on path
modeling of limbic-frontal circuitry in depression. They
reported that drug treatment responders and non-
responders had different limbic-cortical connections,
non-responders had additional limbic-subcortical
abnormalities, and there were limbic-cortical and cor-
tico-cortical differences between cognitive-behavior ther-
apy responders and pharmacotherapy responders.
fMRI has become a reasonable and economical substi-
tute for PET. Blood oxygen level-dependent (BOLD)
refers to the MRI contrast of oxygenated with deoxyge-
nated blood, and allows MRI measurement of rCBF.
Knowledge of specific pathways involved in OCD and
TRD is obviously critical to further advances in the uses
of DBS for psychiatric disorders. Tractography, also
known as diffusion tensor imaging, is a relatively new
procedure for determining functional connections
between brain locations in living humans. Although the
mathematics involved is complex, the MRI is simply
used to measure the movement of oxygen along path-
ways from a “seed” voxel to areas that receive signals
from the seed. A good discussion on it has been made
by Taylor [43].
More germane to the DBS discussion, Gutman [3] has
used tractographic analysis to examine the connections
from seeds in the cingulate gyrus (CG) to the AL/IC.
These are the two areas for DBS that are featured pro-
minently in Table 1. They found that CG connected to
the medial frontal cortex, anterior and posterior cingu-
late, medial temporal lobe, medial thalamus, hypothala-
mus, nucleus accumbens and dorsal brain stem. AL/IC
projected to frontal pole, median temporal lobe, cerebel-
lum, nucleus accumbens, thalamus, hypothalamus, and
brainstem. While the two seeds were connected to some
common areas, those connections seemed to be via dif-
ferent white matter bundles. Gutman suggested the two
locations exist within separate neural networks that
include common nodes. Larger studies, including both
control subjects and patients, are needed for further
clarification but until in vivo tract tracing in human is
possible, results cannot be fully verified.
Challenges of DBS clinical trials
The usual ideas about double blind testing and random
selection are not applicable to DBS. Because of the
bimodal nature of the patients’ responses, and the small
sizes of the samples, calculations on sample sizes for a
given level of confidence must be non-parametric (for
example, see Mallet [11]).
1. The patient is always his/her own control. The
simulator can usually be turned off without the
patient aware of the change, but sometimes there is
a dramatic return of symptoms. The clinical rater is
usually blind, but is the study truly double blind if
turning off the stimulator precipitates suicidal idea-
tion or obsessive pre-occupations? Randomization
usually means random assignment to stimulus-first
and sham-first conditions.
2. Recruitment of severe treatment resistant patients
for a neurosurgical procedure has been difficult,
and multi-center studies have been the only way to
enroll meaningful numbers of subjects.
3. Achieving a consensus among Institutional Review
Boards can be both expensive and time consuming.
4. Given the necessity of multi-center studies, one is
left to assume that very complex procedures can be
replicated exactly across different institutions.
As more studies are done, and if DBS becomes cov-
ered by insurance, then random selection of subjects
for alternative DBS targets may become practical and
parametric statistical power calculations will be feasi-
ble. Genetic studies and brain imaging could possibly
improve the selection of probable responders in
future.
Ethical considerations
Many papers listed as reviews also contain comments on
ethics, and the consensus is that modifying personality is
not unethical. But there are other ethical considerations
of DBS that need to be carefully considered. The risks
and benefits of implanting electrodes in the brain must
be weighed carefully as it is an invasive procedure.
There also may be ethical issues involved selecting the
population that receives deep brain stimulation. Would
all people have equal access to treatment? If not, who
would determine when a depression is severe or unre-
sponsive enough for DBS? If it proves effective, should
we allow DBS to be used for neural enhancement?
These issues require comprehensive study beyond the
scope of this paper.
Conclusions
DBS is an expensive treatment and the phase for the
procedure involves considerable time. It is not entirely
without risks, as the adverse events described in the
movement disorders suggest. OCD and TRD reports are
remarkable for their lack of adverse events (other than
those purely related to surgery), but that may reflect the
use of younger subjects.
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of DBS, the number of recovered patients. These
patients were severely ill individuals and all past treat-
ment was unsuccessful. The economics of the matter
would make providing such patients with expensive yet
successful treatment justifiable, as the costs of repeat-
edly failing treatments are huge. From a humanitarian
and financial viewpoint, treatment expense is not a
major issue.
Thus, while still in the research stage, DBS promises
to be a major advance. Modern imaging methods allows
precise placement of electrodes. Electrophysiological
micro-recordings from implanted electrodes before and
during stimulation aid in defining the electrode loca-
tions. Measurement of rCBF before and after stimula-
tion provides additional accuracy. Location and
parameters of the stimulation can be changed to indivi-
dualize and optimize treatment. Since the patient usually
cannot detect whether stimulation is on or off, artificial
stimulation can easily be used to deceive participants
and provide a control condition. This ability to use
patients as their own controls is a powerful tool for
reducing placebo effects.
DBS is a very promising new development for the
treatment of severe treatment-resistant depression and
obsessive-compulsive disorder. So far the clinical sam-
ples are small, and some of the theoretical rationales are
less than clear. Nonetheless, the results so far are very
impressive, and it is certain that present shortcomings
will be addressed in the near future.
Additional file 1: QUOROM Statement Checklist. A PDF document
showing the Quality of Reporting of Meta-analyses (QUOROM) statement
checklist.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-0500-3-60-
S1.PDF]
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